Disease Markers

Disease Markers / 2019 / Article
Special Issue

Find the Essence through the Phenomena: Cardiovascular Diseases and Biomarkers 2019

View this Special Issue

Research Article | Open Access

Volume 2019 |Article ID 7676189 | https://doi.org/10.1155/2019/7676189

Vânia Aparecida Mendes Goulart, Anderson Kenedy Santos, Valéria Cristina Sandrim, Josimar Marques Batista, Mauro Cunha Xavier Pinto, Luiz Cláudio Cameron, Rodrigo Ribeiro Resende, "Metabolic Disturbances Identified in Plasma Samples from ST-Segment Elevation Myocardial Infarction Patients", Disease Markers, vol. 2019, Article ID 7676189, 10 pages, 2019. https://doi.org/10.1155/2019/7676189

Metabolic Disturbances Identified in Plasma Samples from ST-Segment Elevation Myocardial Infarction Patients

Guest Editor: Zhongjie Shi
Received21 Jan 2019
Revised07 May 2019
Accepted16 May 2019
Published01 Jul 2019


ST-segment elevation myocardial infarction (STEMI) is the most severe form of myocardial infarction (MI) and the main contributor to morbidity and mortality caused by MI worldwide. Frequently, STEMI is caused by complete and persistent occlusion of a coronary artery by a blood clot, which promotes heart damage. STEMI impairment triggers changes in gene transcription, protein expression, and metabolite concentrations, which grants a biosignature to the heart dysfunction. There is a major interest in identifying novel biomarkers that could improve the diagnosis of STEMI. In this study, the phenotypic characterization of STEMI patients () and healthy individuals () was performed, using a target metabolomics approach. Plasma samples were analyzed by UPLC-MS/MS (ultra-high-performance liquid chromatography-tandem mass spectrometry) and FIA-MS (MS-based flow injection analysis). The goal was to identify novel plasma biomarkers and metabolic signatures underlying STEMI. Concentrations of phosphatidylcholines, lysophosphatidylcholines, sphingomyelins, and biogenic amines were altered in STEMI patients in relation to healthy subjects. Also, after multivariate analysis, it was possible to identify alterations in the glycerophospholipids, alpha-linolenic acid, and sphingolipid metabolisms in STEMI patients.

1. Introduction

Myocardial infarction (MI) is a heart blood flow disruption that leads to tissue damage and cell death in the heart muscle. This pathology presents a high incidence worldwide, and it is a common cause of death and disability in humans [1]. MI has two major clinical manifestations: non-ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI), which is the more severe form and main contributor to morbidity and mortality by MI [24]. STEMI results from the abrupt occlusion of an epicardial coronary artery; as a consequence, the myocardium distal to the occlusion site becomes ischemic [5, 6].

During the ischemic process, oxygen supply is interrupted, and mitochondrial oxidative phosphorylation rapidly stops, with a massive reduction of ATP production from energy metabolism. A compensatory increase in anaerobic glycolysis for ATP production leads to the accumulation of hydrogen ions and lactate, resulting in intracellular acidosis and inhibition of glycolysis, as well as mitochondrial fatty acid and residual energy metabolism. Impaired contraction with persistent electrical activity (excitation-contraction uncoupling) is developed in association with alterations in ion transport systems in the sarcolemma and organellar membranes [68].

In addition to the osmotic and ionic imbalance, the membrane depolarization also activates the voltage-dependent Ca2+ channels, raising levels of intracellular Ca2+. The rapid increase of intracellular calcium is due to the influx through the membrane and by the release of Ca2+ present in the mitochondria and in the cytoplasmic reticulum. Excessive cytosolic Ca2+ leads to the activation of calcium-dependent proteases, phospholipases, lipases, ATPases, and endonucleases. Activation of these enzymes alters cell function, destabilizes the structure of plasma membrane and cytoskeleton, increases lipolysis by free fatty acid metabolism, induces superoxide radical production, promotes DNA damage, and ultimately leads to cell death [912].

STEMI injury triggers changes in gene transcription, protein expression, and metabolite concentrations, which grant a biosignature of the heart dysfunction [1315]. Detection of these biochemical changes has resulted in the discovery of emerging biomarkers, such as myoglobin, total creatine kinase (CK), CK-myocardial band, troponin I (cTnI), and troponin T (cTnT) [16]. However, the efficacy of these STEMI biomarkers is questionable because of the low sensitivity (35% for CK-MB and cTnI) and specificity (85 and 86% for CK-MB and cTnI, respectively) in the first 8 h after injury [15, 17].

The low sensitivity and specificity of biomarkers added to the fact that they can only be detected at least six hours after symptoms onset and that the MI diagnosis is based, besides other factors, in symptoms, that can vary individually, lay emphasis on the importance of the improvement of a biochemical diagnosis of MI [3, 5, 18].

The metabolomics approach has demonstrated great utility in the biomarker discovery field, as well as in detecting changes in biological pathways and in providing information on the mechanisms underlying various conditions, including cardiovascular diseases [1921]. It is based on the global quantitative measurement of low molecular weight endogenous metabolites in tissues or biological fluids [22]. In this study, a target metabolomics approach was used to characterize the phenotypes of STEMI patients and healthy individuals. The overarching goal was to identify novel plasma biomarkers and metabolic signatures underlying STEMI.

2. Methods

2.1. Study Population

The study was conducted according to the Declaration of Helsinki, and its protocol was approved by the Ethics Committee in Research of Santa Casa Misericórdia of Belo Horizonte under number 064/2009. All subjects that agreed to participate prior to their inclusion in the study have signed an informed consent form. STEMI patients were screened based on the following inclusion criteria: age 40-80 years, gender-balanced, chest pain above 20 minutes, and electrocardiographic (ECG) features consistent with STEMI: coronary stenosis with minimal commitment of 70% of the arterial lumen in at least one coronary artery, based on the angiography results (Table 1). The exclusion criteria were as follows: prior history of myocardial infarction or stroke, non-ST-segment elevation myocardial infarction, or other acute coronary syndromes.

Affected arteriesCases (%)

One artery
Left anterior descending coronary artery (LAD)5 (33.3)
Right coronary artery (RCA)1 (6.6)
Left circumflex coronary artery (LCX)1 (6.6)
Two arteries
Right coronary artery+left anterior descending coronary artery3 (20)
Right coronary artery+left circumflex coronary artery3 (20)
Left anterior descending coronary artery+posterior descending artery2 (13.3)

Information obtained through coronary angiography.

The control group was compound on 19 individuals who had never had heart disease or stroke. All participants were recruited from the Clinics Hospital of the Federal University of Minas Gerais (Belo Horizonte, MG, Brazil) and Santa Casa of BH (Belo Horizonte, MG, Brazil). The demographic characteristics of the patients and controls are shown in Table 2.

PatientsAgeSAH (%)Smoking (%)Dyslipidemia (%)Type 2 diabetes mellitus (%)

Male866.72 (±4.92)50.062.512.512.5
Female769.43 (±9.95)57.228.528.542.8
Male955.56 (±12.07)44.444.4
Female1058.30 (±7.70)70.030.0

Mean (±SD). SAH: systemic arterial hypertension.
2.2. Sample Analysis

Blood samples were collected using tubes from the Vacuette® system, and 4 mL were stored in anticoagulant ethylenediaminetetraacetic acid (EDTA) to obtain plasma. The blood samples obtained were rapidly centrifuged at 3.000 rotations per minute (RPM) for 10 minutes to separate the plasma samples and then were distributed in several aliquots into microtubes and immediately stored at -80°C. Plasma samples () were obtained up to seven hours after hospitalization.

A targeted metabolomics approach was used to analyze plasma samples from STEMI patients and controls. The sample preparation and analysis procedures were performed according to the AbsoluteIDQp180 kit (Biocrates Life Sciences AG, Innsbruck, Austria). This kit allows the measurement of metabolites by UPLC-MS/MS (ultra-high performance liquid chromatography-tandem mass spectrometry) and FIA-MS (MS-based flow injection analysis). Briefly, the samples were added to the center of a filter on the upper 96-well plate in 10 μL aliquots per well and dried using a nitrogen evaporator. Subsequently, 50 μL of a 5% solution of phenyl isothiocyanate was added for derivatization of the amino acids and biogenic amines. After incubation, the filter spots were dried again using the nitrogen evaporator.

The metabolites were extracted using 300 μL of 5 mM ammonium acetate in methanol solution and transferred by centrifugation into the lower 96-deep well plate. From the obtained extract, 150 μL was diluted with the same volume of H20 and submitted to UPLC-MS/MS for amino acid and biogenic amine measurements. The remainder of the extract was diluted with 400 μL of mass spectrometry running solvent for further MS analysis lipid detection. The UPLC-MS/MS system was equipped with an Acquity UPLC BEH C18 column (1.7 μm, ) (Waters Chromatography, Dublin, Ireland) connected to Xevo TQ-S mass spectrometers (Waters Technologies, Massachusetts, USA), and the samples were analyzed in positive mode.

The identification and quantification of the metabolites were achieved using internal standards and multiple reaction monitoring (MRM) detection. FIA-MS analysis was performed using the tandem quadrupole mass spectrometer Xevo-TQ-S (Waters Technologies, Massachusetts, USA) also in positive mode. The data analysis and calculation of the metabolite concentrations analyzed by FIA (acylcarnitines, glycerophospholipids, sphingolipids, and hexoses) were automated using MetIDQ software (Biocrates Life Sciences AG, Innsbruck, Austria), an integral part of the kit that imports Waters’ raw data files. The peaks obtained by UPLC (amino acids and biogenic amines) were analyzed using the Target Lynx Application Manager (Waters Technologies, Massachusetts, USA).

2.3. Statistical Analysis

The dataset was analyzed by univariate and multivariate methods. IBM SPSS (International Business Machines, New York, USA) software and the web server MetaboAnalyst 3.0 (http://www.metaboanalyst.ca) were used to develop the univariate analyses, specifically the Wilcoxon-Mann-Whitney test. These methods were used to identify the variables (metabolites) that presented statistically significant differences () in concentrations between the groups studied.

For the multivariate analysis, the software SIMCA 14.0 (Umetrics, Umeå, Sweden) was used. The dataset containing the statistically significant variables were submitted to normalization by unit variance (UV) scaling and then to principal component analysis (PCA), partial least squares discriminant analysis (PLS-DA), and orthogonal projection to latent structure discriminant analysis (OPLS-DA) [23]. The unsupervised method, principal component analysis (PCA), was performed to verify the trends of separation between groups. Then, PLS-DA was performed. This classification technique finds the components or latent variables which discriminate as much as possible between two or more different groups of samples (X block), according to their maximum covariance with target classes (concentrations of metabolites) defined in the Y data block [24]. By relating a data matrix containing independent variables from samples (concentration values) to a matrix containing dependent variables (classes) for these samples, OPLS-DA can remove variations from the independent variables that are not correlated to the dependent variables and enables reducing the model complexity with preserved prediction ability [25].

The models were evaluated using the goodness-of-fit parameter () and the predictive ability parameter (). represents the proportion of variance explained by a given component in the model, whereas is defined as the proportion of variance in the data predictable model under cross-validation [26]. The ranges from 0 to 1, with higher levels indicating more predictive accuracy, whereas indicates perfect predictability [26, 27]. OPLS-DA models were examined to determine which variables were more responsible for any observed separation between groups.

To identify which variables were responsible for this separation, the variable influence on the projection (VIP) parameter was used to select variables that have the more significant contribution in discriminating between metabolomics profiles of ischemic stroke patients, STEMI, and controls. VIP scores indicate the importance of the variable to the whole model [28]. The independent variable evaluation contributes to predictions, and it is an important aspect in the multivariate classification models [29]. In our work, the independent variables were metabolite concentrations and the observation of the regression coefficients allowed us to identify which ones were more positively (high content) or negatively (low content) related to a predicted class. The web server MetaboAnalyst 3.0 (http://www.metaboanalyst.ca) was used for the construction of heatmaps and for the analysis of metabolic pathways.

3. Results

Concentrations of 184 metabolites were analyzed in plasma samples from STEMI patients and healthy volunteers (controls). The unsupervised PCA was first applied to explore correlations between healthy subjects and STEMI patients. According to the PCA analysis of score plots, there was a tendency towards the separation of the STEMI patients and controls (Figure 1).

In addition to PCA analysis, we used the same dataset for PLS-DA analyses. Permutation testing and seven-fold cross-validation, two established methods of internal validation, were used to confirm model validity. Permutation tests involve the random assignment of class labels to cases and controls [26]. The seven-fold cross-validation step involves omitting a portion of the data from model development, developing parallel models from the reduced data, predicting the omitted data from the different models, and then comparing predicted with actual values, providing an estimate of overall predictive power [30]. The obtained results demonstrated evident discrimination between the metabolic profiles (Figure 2(a)). The PLS-DA model presented high predictive and adjustment capacity (, ) through cross-validation. Additionally, the permutation test plot () showed intercepts: and 0.564; and 0.152, indicating that this PLS-DA model is not overfitting and is valid for this metabolomics profiling (Figure 2(b)).

The best visualization of the discrimination between STEMI and controls was obtained through the construction of the model by OPLS-DA (Figure 3). This model, as well as PLS-DA, was validated using a seven-fold cross-validation step as internal validation. After validation, the quality parameters obtained were and .

To verify which independent variables (metabolites) were more important for the classification between the groups using OPLS-DA, the VIP scores were calculated. By combining the VIP with the results from the univariate statistical analysis, we could select the differential metabolites between STEMI patients and controls. Sixty metabolites with VIP were found; among them, 44 presented a statistical difference () between STEMI and controls (Table 3). Of these metabolites, 41 had an identification record in the HMDB (Human Metabolome Database, http://www.hmdb.ca/). The differences in concentration of these metabolites among the samples are demonstrated in the heatmaps (Figure 4(a)), and the difference between groups is demonstrated in Figure 4(b) and in the graphic of concentrations (Figure 1S of the Supplementary Material). In the heatmaps, metabolites were clustered according to their Pearson correlation coefficients.

No.MetabolitesClassesVIPaFCb valuec valuedSTEMIControls

1PC ae C36:4Phosphatidylcholines1,49-3.690.00030.0049UpDown
2PC ae C36:3Phosphatidylcholines1,481.980.00210.0140DownUp
3PC ae C34:2Phosphatidylcholines1,471.050.80820.8841DownUp
4PC ae C38:5Phosphatidylcholines1,44-3.650.00140.0119UpDown
5PC ae C38:6Phosphatidylcholines1,422.27< 0.00010.0000DownUp
6PC ae C34:3Phosphatidylcholines1,391.920.00200.0140DownUp
7PC aa C34:4Phosphatidylcholines1,39-2.40.00760.0285UpDown
8PC ae C40:3Phosphatidylcholines1,38-2.290.04420.0913UpDown
9PC aa C40:2Phosphatidylcholines1,371.220.53240.6310DownUp
10PC ae C40:6Phosphatidylcholines1,351.640.00220.0142DownUp
11lysoPC a C14:0Lysophosphatidylcholines1,351.680.00040.0049DownUp
12PC aa C36:1Phosphatidylcholines1,331.7< 0.00010.0017DownUp
13PC aa C36:3Phosphatidylcholines1,33-3.290.03020.0729UpDown
14PC ae C36:5Phosphatidylcholines1,32-1.210.71570.8035UpDown
15PC ae C32:1Phosphatidylcholines1,321.140.00760.0285DownUp
16PC aa C36:0Phosphatidylcholines1,32-1.440.01360.0426UpDown
17PC aa C40:3Phosphatidylcholines1,303.00.02640.0663DownUp
18PC ae C38:4Phosphatidylcholines1,29-3.690.00030.0049UpDown
19PC aa C38:3Phosphatidylcholines1,291.540.00030.0049DownUp
20PC aa C42:4Phosphatidylcholines1,28-1.60.00450.0190UpDown
21SM C26:0Sphingomyelins1,272.420.00020.0036DownUp
22lysoPC a C18:2Lysophosphatidylcholines1,251.580.00450.0190DownUp
23PC aa C30:0Phosphatidylcholines1,231.820.00040.0049DownUp
24PC ae C42:1Phosphatidylcholines1,22-1.350.14010.2330UpDown
25PC ae C38:3Phosphatidylcholines1,222.230.08600.1594DownUp
26PC ae C36:2Phosphatidylcholines1,21-4.020.03150.0733UpDown
27PC ae C34:1Phosphatidylcholines1,201.050.53240.6310DownUp
28Nitro-TyrBiogenic amines1,20-2.180.00080.0075UpDown
29PC aa C38:5Phosphatidylcholines1,201.87<0.00010.0017DownUp
30SM (OH) C24:1Sphingomyelins1,19-1.140.17600.2715DownDown
31lysoPC a C20:3Lysophosphatidylcholines1,191.040.37640.4824DownUp
32PC ae C38:1Phosphatidylcholines1,17-2.110.01830.0533UpDown
33PC ae C44:3Phosphatidylcholines1,16-1.320.34880.4603DownDown
34Ac-OrnBiogenic amines1,161.820.00390.0190DownUp
35PC aa C40:5Phosphatidylcholines1,15-2.440.02010.0548UpDown
36PC ae C32:2Phosphatidylcholines1,151.550.00050.0052DownUp
37PC ae C30:1Phosphatidylcholines1,151.980.01590.0474DownUp
38PC ae C40:4Phosphatidylcholines1,14-1.680.00440.0190DownDown
39PC aa C40:1Phosphatidylcholines1,13-1.440.03760.0829UpDown
40SM (OH) C14:1Sphingomyelins1,131.070.27460.3779DownUp
41PC ae C34:0Phosphatidylcholines1,13-1.420.91710.9403UpDown
42SM C24:0Sphingomyelins1,131.410.00010.0035DownUp
43PC aa C38:4Phosphatidylcholines1,13-2.040.16000.2561UpDown
44lysoPC a C16:1Phosphatidylcholines1,121.590.00800.0293DownUp
45PC aa C40:6Phosphatidylcholines1,11-1.020.03290.0738UpDown
46SM (OH) C22:1Sphingomyelins1,111.550.01190.0391DownUp
47PC aa C38:0Phosphatidylcholines1,111.290.01130.0388DownUp
48SM (OH) C22:2Sphingomyelins1,111.620.00180.0136DownUp
49PC aa C42:2Phosphatidylcholines1,10-1.440.02010.0548UpDown
50PC ae C44:5Phosphatidylcholines1,10-1.580.23820.3397UpDown
51PC ae C44:6Phosphatidylcholines1,07-1.720.35800.4675UpDown
52lysoPC a C18:1Lysophosphatidylcholines1,071.270.03290.0738DownUp
53PC aa C24:0Phosphatidylcholines1,07-1.770.00900.0321UpDown
54PC aa C38:6Phosphatidylcholines1,061.690.00090.0084DownUp
55PC aa C28:1Phosphatidylcholines1,031.480.02630.0663DownUp
56PC ae C30:0Phosphatidylcholines1,031.580.17610.2715DownUp
57PC ae C38:2Phosphatidylcholines1,02-1.810.00330.0184UpDown
58lysoPC a C18:0Lysophosphatidylcholines1,011.210.03150.0733DownUp
59PC aa C40:4Phosphatidylcholines1,011.410.00400.0190DownUp
60PC aa C32:0Phosphatidylcholines1,01-1.50.98620.9862UpDown

aVariable importance in the projection (VIP) was obtained from OPLS-DA with a threshold of 1.0. bThe fold change (FC) was calculated by the average value of the STEMI group to that of the control group. c value was calculated by the Wilcoxon-Mann-Whitney test. values < 0.05 are in bold. d value was the adjusted value with the false discovery rate (FDR).

This panel containing 41 metabolites was used to investigate the metabolic pathways associated with STEMI. Significantly altered pathways () that also had high impact values include glycerophospholipid metabolism, alpha-linolenic acid metabolism, and sphingolipid metabolism (Figure 5). Pathway significance was determined from pathway enrichment analysis and based upon the values for each compound in the dataset. The impact value, on the other hand, was determined by pathway topology analysis. Impact represents the importance of a metabolite within a pathway; a metabolite that is found at a junction point within a pathway may have a greater impact on the pathway function if the level is altered.

The phosphatidylcholines were the main group of metabolites that showed a difference between STEMI and controls: 15 were in lower concentration and 16 in higher concentration in patients with STEMI. Four lysophosphatidylcholines and four sphingomyelins showed a lower concentration in patients with STEMI. Two biogenic amines showed a difference in STEMI: one showed high concentration and the other lower concentration (Figure 4(b)). Differences in amino acid, acylcarnitines, and hexoses concentrations between the two groups were not found.

According to the statistical model, there were no significant differences between groups related to the quantified metabolites, coronary arteries committed, and comorbidities (systemic arterial hypertension, type II diabetes mellitus, and dyslipidemia) (Tables 1 and 2). Patients with STEMI presented similar metabolic profiles, despite these variables.

4. Discussion

For more than three decades, the glycerophospholipid hydrolysis in a cardiomyocyte membrane during ischemia has been linked to the pathogenesis of myocardial infarction [31, 32]. The contribution of phospholipid metabolism to plasma membrane disruption in necrotic cell death induced by hypoxia or ischemia has been classically attributed to the action of phospholipases, loss of asymmetry, or the accumulation of bilayer-disrupting amphiphilic lipids, such as lysophospholipid [12]. In general, alterations in myocardial lipid metabolism during ischemia/reperfusion can be classified into two groups: (1) changes in fatty acid β-oxidation and (2) changes mediated by the activation of phospholipases and other lipid catabolic enzymes (e.g., ceramidase and sphingomyelinase) that target the structurally important lipid constituents of cellular membrane structures of the heart [8].

The major lipids present in the eukaryotic cell membrane are glycerophospholipids, sterols, and sphingolipids [15]. According to our results, the main metabolic pathway associated with STEMI is the metabolism of glycophospholipids, followed by alpha-linoleic acid metabolism and sphingolipid metabolism. The major classes of glycerophospholipid include phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, and phosphatidic acid [14]. Plasmalogens are unique phospholipid species particularly derived from phosphatidylcholine (PC) or phosphatidylethanolamine (PE); they are characterized by the presence of a vinyl-ether bond and an ester bond at the sn-1 and sn-2 positions, respectively, of the glycerol backbone [33]. On the basis of their polar head groups at the sn-3 position, plasmalogens are mainly classified into either choline plasmalogens or ethanolamine plasmalogens [34].

Glycerophospholipids have received special attention in research on myocardial infarction and its causes [19, 22]. Phosphatidylcholine is the principle phospholipid in the mammalian heart [21]. The human cardiomyocytes are composed of approximately 40% of phosphatidylcholines [20, 21]. Compared to the control group, we found 15 phosphatidylcholines in a lower concentration in the plasma of STEMI patients. In a cardiac tissue, previous studies reported the inhibition of phosphatidylcholine synthesis during hypoxia or ischemia. Hatch and Choy described the inhibition of phosphatidylcholine synthesis in perfused hearts undergoing hypoxia [35], phosphatidylcholine synthesis was also impaired by hypoxia in isolated rat ventricular myocytes [36], and a net loss of choline after global ischemia has been recently demonstrated in reperfused rat hearts [37]. In this context, several authors suggested that the depletion of ATP and CTP was the cause of the reduced phosphatidylcholine synthesis [35, 38, 39].

Recently, it has been shown in two apparently healthy middle-aged adult cohorts that serum concentrations of four sphingomyelins and six phosphatidylcholines were associated with a higher risk of STEMI, regardless of several risk factors for cardiovascular disease. These are PC aa C38:3, PC aa C40:4, PC ae C36:3, PC ae C38:3, PC ae C38:4, and PC ae C40:3, as well as sphingomyelins C16:0, C24:0, and C16:1 and hydroxy-sphingomyelin C22:1 [21]. According to our results, seven of these markers prevailed after STEMI, two in higher concentrations in relation to the control group (PC ae C38:4 and PC ae C40:3) and five in lower concentrations (PC aa C38:3, PC aa C40, and PC ae C36:3; sphingomyelins C24:0 and hydroxy-sphingomyelin C22:1). Some biologically active substances during ischemia, for example, tumor necrosis factor-α (TNF-α), may induce the synthesis of ceramide from sphingomyelin via sphingomyelinase. Ceramide, in turn, may act as a second messenger, promoting cardiomyocyte apoptosis [40, 41]. This may be an explanation for the decrease of sphingomyelins in STEMI patients.

Substantial evidence accumulated in the last decade indicates that glycerophospholipids, specifically plasmalogens, could represent a major lipid-soluble antioxidant component [4244]. This proposal is based on the ability of the plasmalogens to scavenge several reactive oxygen species, their relatively high concentrations in cardiac tissue, and their subcellular and extracellular locations in close vicinity to the oxidizable substrates [34, 39]. In this way, oxidative stress can be a justification for the decrease of phosphatidylcholines (choline plasmalogens) in myocardial infarction.

On the other hand, we found 16 phosphatidylcholines in higher concentration in STEMI patients. Furthermore, orthogonal partial least squares discriminant analysis (OPLS-DA) indicated that STEMI patients can be differentiated from healthy volunteers by the phosphatidylcholine PC ae C36:4. Some hypotheses may be suggested to justify these results: the wide variety of phospholipase A and their selectivity to certain substrates [45, 46] and the activation enzyme kinetics [47]. Using Langdorf rabbits as an experimental model of global myocardial ischemia, Hazen and colleagues analyzed the action of the calcium-independent plasmalogen-selective phospholipases A2 enzyme. It was reported that membrane-associated calcium-independent plasmalogen-selective phospholipase A2 activity increased over 400% during 2 min of global ischemia, was nearly maximally activated (greater than 10-fold) after only 5 min of ischemia, and remained activated throughout the entire ischemic interval examined (2-60 min). The activation of membrane-associated plasmalogen-selective phospholipase A2 after 5 min of myocardial ischemia was rapidly reversible during reperfusion of ischemic tissue [8]. This example suggests that after reperfusion, past the process of injury and inflammation, phospholipid biosynthesis may increase during the repair process in the same way as it occurs with cholesterol and other biomolecules [48].

A reduction in four lysophospholipids was also observed in STEMI patients (lysoPC a C18:1, lysoPC an 18:0, lysoPC a C14:0, and lysoPC a C16:1) when compared to healthy volunteers. The results of Zhu and colleagues corroborate our findings [49]. Using the UHPLC method, they observed a reduction of three lysophospholipids (lysoPC a C18:2, lysoPC a C16:0, and lysoPC a C18:1) in serum concentration from MI patients. The difference between our works lies in the fact that their samples were collected in the period of 1-6 months after the infarction [49]. Interestingly, it can be observed that one of the potential markers found in STEMI patients in the acute phase (lysoPC an 18:1) are also present in the chronic phase of the disease.

Nitrotyrosine is produced by the modification of protein tyrosine residues by peroxynitrite generated from the reaction of nitric oxide (NO) and superoxide [50]. In our study, it was found to be increased in STEMI patients. This increase has already been reported in patients with cardiovascular pathologies, being considered a transient change during myocardial ischemia [51, 52]. Regarding acetylornithine, its decrease was reported in the early stages of cardiotoxicity induced by a potent chemotherapeutic agent, doxorubicin in male B6C3F1 mice, but its implication on human myocardial infarction is described here for the first time [53].

In this study, we did not find a significant difference between STEMI patients and controls in the metabolic classes: amino acids, acylcarnitines, and hexoses. It has been reported that the amino acid concentration increasing is related to the major risk of adverse events and death in STEMI patients after primary percutaneous coronary intervention [9, 10]. Elevated levels of acylcarnitines were associated with a higher risk of myocardial infarction and diabetes mellitus. Despite this, in this work, we did not find metabolic differences between STEMI patients with diabetes mellitus and STEMI patients without this disease, and neither did we observe alterations in hexoses concentrations. Other works with bigger samples have demonstrated that glycemic alterations can be related to worse prognosis and with a smaller capacity of myocardial regeneration/healing [54, 55].

5. Conclusion

In conclusion, the present study suggests that there are significant alterations in the metabolism of glycerophospholipids, alpha-linolenic acid metabolism, and sphingolipid metabolism in STEMI patients. These changes were observed in the concentrations of 31 phosphatidylcholines, four lysophosphatidylcholines, four sphingomyelins, and two biogenic amines. Although this work had a limitation in the number of samples, the results confirm trends exhibited in previous studies. In addition, this work points to metabolites with a great potential to be biomarkers for STEMI and for the study of new pharmacological targets.

Data Availability

The data used to support the findings of this study are available from the corresponding authors upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


This study was supported by the National Council for Scientific and Technological Development (CNPq, Brazil) and Nanocell Institute. The authors would like to thank the Universidade Federal de Minas Gerais and Waters Technologies of Brazil.

Supplementary Materials

Figure 1S: mean of metabolic concentrations. All presented metabolites have a value < 0.05 and VIP scores (variable influence on the projection) greater than 1. (Supplementary Materials)


  1. E. J. Benjamin, S. S. Virani, C. W. Callaway et al., “Heart disease and stroke statistics—2018 update: a report from the American Heart Association,” Circulation, vol. 137, no. 12, pp. e67–e492, 2018. View at: Publisher Site | Google Scholar
  2. B. Ibanez, S. James, S. Agewall et al., “2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 39, no. 2, pp. 119–177, 2018. View at: Publisher Site | Google Scholar
  3. A. Kumar and C. P. Cannon, “Acute coronary syndromes: diagnosis and management, part I,” Mayo Clinic Proceedings, vol. 84, no. 10, pp. 917–938, 2009. View at: Publisher Site | Google Scholar
  4. D. J. Hausenloy, H. E. Botker, T. Engstrom et al., “Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations,” European Heart Journal, vol. 38, no. 13, pp. 935–941, 2017. View at: Publisher Site | Google Scholar
  5. B. Ibáñez, G. Heusch, M. Ovize, and F. van de Werf, “Evolving therapies for myocardial ischemia/reperfusion injury,” Journal of the American College of Cardiology, vol. 65, no. 14, pp. 1454–1471, 2015. View at: Publisher Site | Google Scholar
  6. A. Deshpande and Y. Birnbaum, “ST-segment elevation: distinguishing ST elevation myocardial infarction from ST elevation secondary to nonischemic etiologies,” World Journal of Cardiology, vol. 6, no. 10, pp. 1067–1079, 2014. View at: Publisher Site | Google Scholar
  7. D. C. Crossman, “The pathophysiology of myocardial ischaemia,” Heart, vol. 90, no. 5, pp. 576–580, 2004. View at: Publisher Site | Google Scholar
  8. G. Heusch and B. J. Gersh, “The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge,” European Heart Journal, vol. 38, no. 11, pp. 774–784, 2016. View at: Publisher Site | Google Scholar
  9. X. du, H. You, Y. Li et al., “Relationships between circulating branched chain amino acid concentrations and risk of adverse cardiovascular events in patients with STEMI treated with PCI,” Scientific Reports, vol. 8, no. 1, article 15809, 2018. View at: Publisher Site | Google Scholar
  10. A. Vignoli, L. Tenori, B. Giusti et al., “NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the AMI-Florence II cohort,” BMC Medicine, vol. 17, no. 1, p. 3, 2019. View at: Publisher Site | Google Scholar
  11. M. Neri, I. Riezzo, N. Pascale, C. Pomara, and E. Turillazzi, “Ischemia/reperfusion injury following acute myocardial infarction: a critical issue for clinicians and forensic pathologists,” Mediators of Inflammation, vol. 2017, Article ID 7018393, 14 pages, 2017. View at: Publisher Site | Google Scholar
  12. C. F. Yang, “Clinical manifestations and basic mechanisms of myocardial ischemia/reperfusion injury,” Tzu Chi Medical Journal, vol. 30, no. 4, pp. 209–215, 2018. View at: Publisher Site | Google Scholar
  13. M. Cheng, S. An, and J. Li, “Identifying key genes associated with acute myocardial infarction,” Medicine, vol. 96, no. 42, article e7741, 2017. View at: Publisher Site | Google Scholar
  14. S. E. Ali, M. A. Farag, P. Holvoet, R. S. Hanafi, and M. Z. Gad, “A comparative metabolomics approach reveals early biomarkers for metabolic response to acute myocardial infarction,” Scientific Reports, vol. 6, no. 1, article 36359, 2016. View at: Publisher Site | Google Scholar
  15. V. N. Silbiger, A. D. Luchessi, R. D. C. Hirata et al., “Time course proteomic profiling of human myocardial infarction plasma samples: an approach to new biomarker discovery,” Clinica Chimica Acta, vol. 412, no. 11-12, pp. 1086–1093, 2011. View at: Publisher Site | Google Scholar
  16. S. Mythili and N. Malathi, “Diagnostic markers of acute myocardial infarction,” Biomedical Reports, vol. 3, no. 6, pp. 743–748, 2015. View at: Publisher Site | Google Scholar
  17. A. H. Wu, Y. J. Feng, J. H. Contois, and S. Pervaiz, “Comparison of myoglobin, creatine kinase-MB, and cardiac troponin I for diagnosis of acute myocardial infarction,” Annals of Clinical and Laboratory Science, vol. 26, no. 4, pp. 291–300, 1996. View at: Google Scholar
  18. E. Danese and M. Montagnana, “An historical approach to the diagnostic biomarkers of acute coronary syndrome,” Annals of translational medicine, vol. 4, no. 10, pp. 194–194, 2016. View at: Publisher Site | Google Scholar
  19. G. D. Lewis, A. Asnani, and R. E. Gerszten, “Application of metabolomics to cardiovascular biomarker and pathway discovery,” Journal of the American College of Cardiology, vol. 52, no. 2, pp. 117–123, 2008. View at: Publisher Site | Google Scholar
  20. V. T. Dang, A. Huang, and G. H. Werstuck, “Untargeted metabolomics in the discovery of novel biomarkers and therapeutic targets for atherosclerotic cardiovascular diseases,” Cardiovascular & Hematological Disorders Drug Targets, vol. 18, no. 3, pp. 166–175, 2018. View at: Publisher Site | Google Scholar
  21. A. Floegel, T. Kühn, D. Sookthai et al., “Serum metabolites and risk of myocardial infarction and ischemic stroke: a targeted metabolomic approach in two German prospective cohorts,” European Journal of Epidemiology, vol. 33, no. 1, pp. 55–66, 2018. View at: Publisher Site | Google Scholar
  22. X. Gao, C. Ke, H. Liu et al., “Large-scale metabolomic analysis reveals potential biomarkers for early stage coronary atherosclerosis,” Scientific Reports, vol. 7, no. 1, article 11817, 2017. View at: Publisher Site | Google Scholar
  23. J. Bartel, J. Krumsiek, and F. J. Theis, “Statistical methods for the analysis of high-throughput metabolomics data,” Computational and Structural Biotechnology Journal, vol. 4, no. 5, article e201301009, 2013. View at: Publisher Site | Google Scholar
  24. S. Wold, M. Sjöström, and L. Eriksson, “PLS-regression: a basic tool of chemometrics,” Chemometrics and Intelligent Laboratory Systems, vol. 58, no. 2, pp. 109–130, 2001. View at: Publisher Site | Google Scholar
  25. H. Gu, Z. Pan, B. Xi, V. Asiago, B. Musselman, and D. Raftery, “Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer,” Analytica Chimica Acta, vol. 686, no. 1-2, pp. 57–63, 2011. View at: Publisher Site | Google Scholar
  26. M. N. Triba, L. le Moyec, R. Amathieu et al., “PLS/OPLS models in metabolomics: the impact of permutation of dataset rows on the K-fold cross-validation quality parameters,” Molecular BioSystems, vol. 11, no. 1, pp. 13–19, 2015. View at: Publisher Site | Google Scholar
  27. J. F. Hair, G. T. M. Hult, C. M. Ringle, and M. Sarstedt, A Primer on Partial Least Squares Structural Equation Modeling (PLS-SEM), Sage, Thousand Oaks, CA, USA, 2nd edition, 2017.
  28. B. Galindo-Prieto, L. Eriksson, and J. Trygg, “Variable influence on projection (VIP) for orthogonal projections to latent structures (OPLS),” Journal of Chemometrics, vol. 28, no. 8, pp. 623–632, 2014. View at: Publisher Site | Google Scholar
  29. B. Xi, H. Gu, H. Baniasadi, and D. Raftery, “Statistical analysis and modeling of mass spectrometry-based metabolomics data,” Methods in Molecular Biology, vol. 1198, pp. 333–353, 2014. View at: Publisher Site | Google Scholar
  30. J. A. Westerhuis, H. C. J. Hoefsloot, S. Smit et al., “Assessment of PLSDA cross validation,” Metabolomics, vol. 4, no. 1, pp. 81–89, 2008. View at: Publisher Site | Google Scholar
  31. A. T. Turer, “Using metabolomics to assess myocardial metabolism and energetics in heart failure,” Journal of Molecular and Cellular Cardiology, vol. 55, pp. 12–18, 2013. View at: Publisher Site | Google Scholar
  32. M. Nam, Y. Jung, D. H. Ryu, and G. S. Hwang, “A metabolomics-driven approach reveals metabolic responses and mechanisms in the rat heart following myocardial infarction,” International Journal of Cardiology, vol. 227, pp. 239–246, 2017. View at: Publisher Site | Google Scholar
  33. N. E. Braverman and A. B. Moser, “Functions of plasmalogen lipids in health and disease,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1822, no. 9, pp. 1442–1452, 2012. View at: Publisher Site | Google Scholar
  34. J. Lessig and B. Fuchs, “Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis,” Current Medicinal Chemistry, vol. 16, no. 16, pp. 2021–2041, 2009. View at: Publisher Site | Google Scholar
  35. G. M. Hatch and P. C. Choy, “Effect of hypoxia on phosphatidylcholine biosynthesis in the isolated hamster heart,” Biochemical Journal, vol. 268, no. 1, pp. 47–54, 1990. View at: Publisher Site | Google Scholar
  36. P. C. Choy, M. Chan, G. Hatch, and R. Y. K. Man, “Phosphatidylcholine metabolism in ischemic and hypoxic hearts,” Molecular and Cellular Biochemistry, vol. 116, no. 1-2, pp. 53–58, 1992. View at: Publisher Site | Google Scholar
  37. A. Bruhl, G. Hafner, and K. Loffelholz, “Release of choline in the isolated heart, an indicator of ischemic phospholipid degradation and its protection by ischemic preconditioning: no evidence for a role of phospholipase D,” Life Sciences, vol. 75, no. 13, pp. 1609–1620, 2004. View at: Publisher Site | Google Scholar
  38. A. Lochner and M. de Villiers, “Phosphatidylcholine biosynthesis in myocardial ischaemia,” Journal of Molecular and Cellular Cardiology, vol. 21, no. 2, pp. 151–163, 1989. View at: Publisher Site | Google Scholar
  39. I. Sutter, R. Klingenberg, A. Othman et al., “Decreased phosphatidylcholine plasmalogens--a putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction,” Atherosclerosis, vol. 246, pp. 130–140, 2016. View at: Publisher Site | Google Scholar
  40. M. Knapp, M. Żendzian-Piotrowska, A. Błachnio-Zabielska, P. Zabielski, K. Kurek, and J. Górski, “Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat,” Basic Research in Cardiology, vol. 107, no. 6, p. 294, 2012. View at: Publisher Site | Google Scholar
  41. S. Borodzicz, K. Czarzasta, M. Kuch, and A. Cudnoch-Jedrzejewska, “Sphingolipids in cardiovascular diseases and metabolic disorders,” Lipids in Health and Disease, vol. 14, no. 1, p. 55, 2015. View at: Publisher Site | Google Scholar
  42. B. Engelmann, “Plasmalogens: targets for oxidants and major lipophilic antioxidants,” Biochemical Society Transactions, vol. 32, no. 1, pp. 147–150, 2004. View at: Publisher Site | Google Scholar
  43. R. A. Zoeller, A. C. Lake, N. Nagan, D. P. Gaposchkin, M. A. Legner, and W. Lieberthal, “Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of the vinyl ether,” Biochemical Journal, vol. 338, Part 3, no. 3, pp. 769–776, 1999. View at: Publisher Site | Google Scholar
  44. D. Reiss, K. Beyer, and B. Engelmann, “Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro,” Biochemical Journal, vol. 323, Part 3, no. 3, pp. 807–814, 1997. View at: Publisher Site | Google Scholar
  45. A. M. Astudillo, M. A. Balboa, and J. Balsinde, “Selectivity of phospholipid hydrolysis by phospholipase A2 enzymes in activated cells leading to polyunsaturated fatty acid mobilization,” Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, vol. 1864, no. 6, pp. 772–783, 2019. View at: Publisher Site | Google Scholar
  46. E. Diez, F. H. Chilton, G. Stroup, R. J. Mayer, J. D. Winkler, and A. N. Fonteh, “Fatty acid and phospholipid selectivity of different phospholipase A2 enzymes studied by using a mammalian membrane as substrate,” The Biochemical Journal, vol. 301, Part 3, no. 3, pp. 721–726, 1994. View at: Publisher Site | Google Scholar
  47. S. L. Hazen, D. A. Ford, and R. W. Gross, “Activation of a membrane-associated phospholipase A2 during rabbit myocardial ischemia which is highly selective for plasmalogen substrate,” Journal of Biological Chemistry, vol. 266, no. 9, pp. 5629–5633, 1991. View at: Google Scholar
  48. M. Pfohl, I. Schreiber, H. M. Liebich, H. U. Häring, and H. M. Hoffmeister, “Upregulation of cholesterol synthesis after acute myocardial infarction--is cholesterol a positive acute phase reactant?” Atherosclerosis, vol. 142, no. 2, pp. 389–393, 1999. View at: Publisher Site | Google Scholar
  49. M. Zhu, Y. Han, Y. Zhang et al., “Metabolomics study of the biochemical changes in the plasma of myocardial infarction patients,” Frontiers in Physiology, vol. 9, p. 1017, 2018. View at: Publisher Site | Google Scholar
  50. R. Radi, “Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects,” Accounts of Chemical Research, vol. 46, no. 2, pp. 550–559, 2012. View at: Publisher Site | Google Scholar
  51. K. Tanabe, Y. Kawai, M. Kitayama et al., “Increased levels of the oxidative stress marker, nitrotyrosine in patients with provocation test-induced coronary vasospasm,” Journal of Cardiology, vol. 64, no. 2, pp. 86–90, 2014. View at: Publisher Site | Google Scholar
  52. G. Peluffo and R. Radi, “Biochemistry of protein tyrosine nitration in cardiovascular pathology,” Cardiovascular Research, vol. 75, no. 2, pp. 291–302, 2007. View at: Publisher Site | Google Scholar
  53. L. K. Schnackenberg, L. Pence, V. Vijay et al., “Early metabolomics changes in heart and plasma during chronic doxorubicin treatment in B6C3F1 mice,” Journal of Applied Toxicology, vol. 36, no. 11, pp. 1486–1495, 2016. View at: Publisher Site | Google Scholar
  54. R. Marfella, M. R. Rizzo, M. Siniscalchi et al., “Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage,” International Journal of Cardiology, vol. 168, no. 4, pp. 3954–3962, 2013. View at: Publisher Site | Google Scholar
  55. C. Sardu, M. Barbieri, M. L. Balestrieri et al., “Thrombus aspiration in hyperglycemic ST-elevation myocardial infarction (STEMI) patients: clinical outcomes at 1-year follow-up,” Cardiovascular Diabetology, vol. 17, no. 1, p. 152, 2018. View at: Publisher Site | Google Scholar

Copyright © 2019 Vânia Aparecida Mendes Goulart et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.